Co-administration of this medicine with antibiotics has not been studied yet. This doesn’t mean interactions don’t exist. Antibiotics might interact with various ARVs causing potential health problems. Do not co-administer these drugs without the help of a medical specialist.
Triumeq is a 3-in-1 drug combination with abacavir, dolutegravir, and lamivudine as active substances. It is an antiretroviral medication, highly potent in suppressing viral replication.
Dolutegravir is an integrase inhibitor, abacavir and lamivudine are nucleoside analogues (also called nukes). Triumeq constitutes a complete treatment regimen.
The active substances in this med interfere with reverse transcriptase and integrase enzymes used by the virus to reproduce itself inside the T-cells (or CD4+ cells) .
Halting of viral replication boost the CD4+ cell count, making the immune function stronger in fighting external opportunistic infections. Triumeq is highly effective in reducing HIV-related mortality, making the patients’ lives healthier and longer.
Triumeq is not to be used by individuals with moderate or severe hepatic impairment. Although most antibiotics are highly effective in preventing serious bacterial infections in HIV infected individuals, and providing a substantial degree of relief from adverse health events , most antibiotics can cause liver injury and other potential serious negative effects.
Antibiotics such as co-trimoxazole induced hepatic injury with hypersensitivity-like reactions when administered. It’s highly recommended to assess the patient’s health for the presence of liver problems if this substance is to be co-administered with Triumeq or other ARV meds .
There is a possible drug interaction between isoniazid and dolutegravir when co-administered. This antibiotic decreased dolutegravir AUC and Cmin by 46% and 74% respectively. Likewise, this interaction can strengthen possible adverse effects of isoniazid (such as vomiting, nausea, flu-like symptoms, and fever).
Rifampin causes a drop in dolutegravir effectiveness and dosage adjustment is needed accordingly. Rifapentine is contraindicated with dolutegravir. This combination causes a potential reduction in dolutegravir effectiveness.
Co-trimoxazole interaction with lamivudine may increase lamivudine AUC by 44%. Nonetheless, no dose adjustment is necessary .
This is not a complete list, and antibiotics analysis is necessary before combining it with Triumeq. Always check with a doctor for safe dose administration.